Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

ment stage company) CONDENSED STATEMENTS OF OPERATIONS (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2009 2008 2009 2008 Operating expenses: Research and development $4,079,979 $11,743,221 $10,219,321 $22,221,268 Marketing 1,186,139 927,275 1,722,254 1,510,977 General and administrative 2,974,605 2,902,894 5,786,352 5,569,932 Other (237,701) - 413,085 28,257 Total operating expenses 8,003,022 15,573,390 18,141,012 29,330,434 Loss from operations (8,003,022) (15,573,390) (18,141,012) (29,330,434) Other (expense) income, net (297,059) (23,446) (596,432) 16,683 Net loss $(8,300,081) $(15,596,836) $(18,737,444)$(29,313,751) Basic and diluted net loss per share(1) $ (0.17) $ (0.41) $ (0.40) $ (0.83) Shares used to compute basic and diluted net loss per share(1) 50,299,362 38,057,485 47,083,492 35,489,290 (1) As a result of the issuance of 12,039,794 shares of common stock pursuant to a private placement in the first quarter of 2009 and 9,240,307 shares of common stock pursuant to an effective shelf registration in the first quarter of 2008, there is a lack of comparability in the per share amounts between the 2009 and 2008 periods presented.

                          CADENCE PHARMACEUTICALS, INC.
                         (a development stage company)
                           CONDENSED BALANCE SHEETS


               
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
3. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... ... office , ... Ill. (Vocus) December 9, 2009 -- As part of ongoing efforts to expand deployment ... in the contaminated soil , sediment and groundwater remediation industry, is ...
... , , WALTHAM, Mass., Dec. 8 ... Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will ... at 8:30 a.m. EST, to discuss results of its Phase 3 ... , This call is being webcast by Thomson/CCBN and can ...
... , CLEVELAND, ... high-performance products to the market with a Smart ... performance and recyclable packaging, Nutek,s products continue to ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091208/CL22934 ) ...
Cached Biology Technology:Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 2Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 3Nutek, LLC Introduces New Soy-Based, Biodegradable Lubricating and Cleaning Wipes 2
(Date:10/14/2014)... (Oct. 14, 2014)—It,s been millions of years since ... team led by Ohio University scientists is breathing life ... airflow through dinosaur snouts. The research has important implications ... breathe but to enhance the sense of smell and ... animals," said Ohio University doctoral student Jason Bourke, lead ...
(Date:10/14/2014)... new kind of stem cell that can become either a ... according to a study published today in the journal ... type contradicts current theory on how organs arise from cell ... of, and future treatment for, liver cancer., Thanks to stem ... being made up of more than 200 cell types. The ...
(Date:10/14/2014)... MA – A team of scientists led by ... (UMMS) and the University of Miami Miller School ... a key genetic pathway underlying bipolar (manic depressive) ... drugs for treating bipolar affective disorder, as well ... The new findings, published online this week in ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... Now, a St. Louis-area teenage boy and a computer ... conducted by a team of neurosurgeons, neurologists, and engineers ... boy, a 14-year-old who suffers from epilepsy, is the ... Invaders, using only the signals from his brain to ...
... In a study appearing in the forthcoming issue of ... Tyre, and Svata M. Louda (all of the University ... aren't all eaten at the same rate. , ... the nutritional quality or defective chemistry of plant tissues. ...
... speed healing at sites of injury - such as heart ... stroke - doctors would like to be able to hasten ... to "mobilize" patients' blood vessel-forming cells, called angiogenic cells, so ... at Washington University School of Medicine in St. Louis demonstrated ...
Cached Biology News:Teenager moves video icons just by imagination 2Teenager moves video icons just by imagination 3Drug can quickly mobilize an army of cells to repair injury 2